Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
2027. jan. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Assessment of genomic instability and homologous recombination repair in ovarian cancer using the Oncomine Comprehensive Assay Plus.
2026. nov. 5.· Oncotarget· PUBMED
Publikáció
Male breast cancer: clinicopathological features and prevalence of germline pathogenic variants.
2026. nov. 4.· Breast cancer research and treatment· PUBMED
Publikáció
Longitudinal Pancreatic Imaging Findings in BRCA1, BRCA2, ATM, and PALB2 Heterozygotes Undergoing Pancreatic Cancer Surveillance: A Prospective PRECEDE Consortium Study.
2026. nov. 3.· JCO precision oncology· PUBMED
Publikáció
Impact of BRCA2, BRCA1, and Other Individual Homologous Recombination Repair Alterations on Survival in Metastatic Castration-resistant Prostate Cancer.
2026. nov. 3.· European urology oncology· PUBMED
Publikáció
The effect of germline mutations on survival outcomes of breast cancer - Study from a tertiary care center in North India.
2026. okt. 29.· Journal of cancer research and therapeutics· PUBMED
Publikáció
Germline BRCA-Lynch syndrome MINAS: report of six Argentinian families and a systematic review of the literature.
2026. okt. 28.· Familial cancer· PUBMED
Publikáció
Multi-omics analysis of high-grade serous ovarian cancers reveals heterogeneity and distinct immunological patterns based upon clinico-genomic status.
2026. okt. 22.· PLoS genetics· PUBMED
Publikáció
Identification and characterization of shared transcriptomic signatures in BRCA2-mutated metastatic breast cancer and lung adenocarcinoma: An integrative bioinformatics approach.
2026. okt. 22.· Mutation research· PUBMED
Publikáció
Correlation between BRCA mutational status and lymph node metastasis in advanced epithelial ovarian cancer: a retrospective study.
2026. okt. 20.· PeerJ· PUBMED
Publikáció
Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study.
2026. okt. 15.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
Cancer risks associated with BRCA1 and BRCA2: Overview and management.
2026. okt. 15.· Cancer· PUBMED
Publikáció
Large-scale integration of functional assay data for the resolution of germline BRCA1 and BRCA2 variants of uncertain significance.
2026. okt. 12.· American journal of human genetics· PUBMED
Publikáció
Case Report: Coexpression of somatic EGFR, BRCA1, and BRCA2 mutations in metastatic non-small cell lung cancer.
2026. okt. 8.· Frontiers in oncology· PUBMED
Publikáció
Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study.
2026. okt. 8.· Nature communications· PUBMED
Publikáció
Re: Targeted Prostate Cancer Screening in BRCA1 or BRCA2 Pathogenic Germline Variant Carriers Detects Clinically Relevant Disease: Five-year Results of the IMPACT Study.
2026. okt. 6.· European urology· PUBMED
Vizsgálat
Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants
2026. okt. 1.· NA · NOT_YET_RECRUITING· CTGOV
Publikáció
Radiogenomic Analysis of Contrast-Enhanced MRI for Predicting Pathogenic BRCA Variants in Ovarian Cancer.
2026. okt. 1.· Acta medica Okayama· PUBMED
Publikáció
Survival After Risk-Reducing Mastectomy in Patients With Pathogenic Variants in BRCA1 and BRCA2: A Network Meta-Analysis.
2026. okt. 1.· JAMA network open· PUBMED
Publikáció
Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions.
2026. okt. 1.· The Journal of clinical investigation· PUBMED
Publikáció
Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer.
2026. okt. 1.· Cancer research communications· PUBMED
Publikáció
Unified genetic risk score for prostate cancer enables improved risk stratification for clinical decision-making.
2026. szept. 29.· Journal of medical genetics· PUBMED
Publikáció
Clinical implications of the type and genomic location of pathogenic BRCA1 and BRCA2 variants in hereditary breast and ovarian cancer.
2026. szept. 29.· Critical reviews in oncology/hematology· PUBMED
Publikáció
Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer.
2026. szept. 29.· European journal of cancer (Oxford, England : 1990)· PUBMED
Publikáció
Risk-reducing salpingo-oophorectomy in patients with gBRCA-mutated breast cancer.
2026. szept. 28.· Archives of gynecology and obstetrics· PUBMED
Publikáció
Clinical impact of ENIGMA-based variant reclassification on genotype-phenotype analyses in BRCA1- and BRCA2-associated hereditary breast and ovarian cancer.
2026. szept. 25.· Breast cancer (Tokyo, Japan)· PUBMED
Publikáció
Pathogenic germline variants in BRCA1/2 are associated with a decreased number of hypomethylated rDNA copies.
2026. szept. 25.· Breast cancer research : BCR· PUBMED
Publikáció
Bridging the BRCA1/2 variant previvor gap in health care.
2026. szept. 24.· JAAPA : official journal of the American Academy of Physician Assistants· PUBMED
Publikáció
Pancreatic Intraductal Papillary Mucinous Neoplasm in a Carrier of a Reported Pathogenic BRCA2 Variant: Diagnostic Considerations and Management Using European and International Guidelines.
2026. szept. 24.· Cureus· PUBMED
Publikáció
Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation.
2026. szept. 23.· Signal transduction and targeted therapy· PUBMED